达格列净在老年2型糖尿病肾病合并高血压患者治疗中的应用效果

doi:10.3969/j.issn.1671-7171.2025.07.031

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1204 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the application effect of dapagliflozin in the treatment of elderly patients with type 2 diabetic nephropathy complicated with hypertension. 【Methods】A total of 92 elderly patients with type 2 diabetic nephropathy complicated with hypertension who were treated in our hospital from March 2021 to March 2024 were selected and divided into the conventional group (given conventional treatment) and the dapagliflozin group (with conventional treatment plus dapagliflozin treatment) according to their medication conditions, with 46 cases in each group. The clinical indicators, renal function indicators, inflammatory indicators, oxidative stress response indicators and adverse reactions before and after treatment were compared between the two groups. 【Results】After treatment, the body mass index (BMI), diastolic blood pressure (DBP), systolic blood pressure (SBP), fasting blood glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol (TC), and triglycerides (TG) of both groups were lower than those before treatment. However, there was no statistically significant difference in the estimated glomerular filtration rate (eGFR) between the two groups (P>0.05). After treatment, the urine microalbumin/creatinine ratio (UACR), homocysteine (Hcy), malondialdehyde (MDA), FPG, HbA1c, C-reactive protein (CRP), interleukin-17 (IL-17), and interleukin-8 (IL-8) levels in the dapagliflozin group were lower than those in the conventional group (P<0.05), while the superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels were higher than those in the conventional group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The application effect of dapagliflozin in the treatment of elderly patients with type 2 diabetic nephropathy complicated with hypertension is significant. It can effectively reduce blood glucose and BMI, improve lipid indicators, protect renal function, reduce inflammatory response, and enhance antioxidant capacity, thereby improving the clinical indicators of patients from multiple aspects and improving their prognosis.

Key words： Diabetes Mellitus, Type 2 Diabetic Nephropathies Hypertension Aged

Received: 20 March 2025

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Huijun

Cite this article:

JIANG Huijun. Application Effect of Dapagliflozin in Elderly Patients with Type 2 Diabetic Nephropathy Complicated by Hypertension[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(7): 1213-1215.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.07.031 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I7/1213

[1] 田蓉,傅桂芬,李丽蓉,等. 老年T2DM合并高血压患者发生糖尿病肾病的影响因素[J].心血管康复医学杂志,2023,32(1):4-8.
[2] 刘晓罡,杨世诚,付乃宽,等. 达格列净对2型糖尿病患者经皮冠状动脉介入治疗术后对比剂肾病发病的影响[J].中国全科医学,2024,27(24):2994-2999.
[3] 常丽,郭东亮,刘继红. 参芎葡萄糖注射液联合达格列净对早期2型糖尿病肾病患者肾功能、尿蛋白的影响[J].分子诊断与治疗杂志,2024,16(5):864-867.
[4] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(基层版)[J].中华全科医师杂志, 2013, 12(8): 675-696.
[5] 中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):792-801.
[6] 钟鸿斌, 谢良地. 中国高血压基层管理指南[M]. 北京:人民卫生出版社, 2015.
[7] 涂常莹,张黎明. 瑞格列奈治疗老年2型糖尿病患者的临床研究[J].中国临床药理学杂志,2023,39(19):2756-2760.
[8] 鲁翠芳,杨斌. 苯磺酸左旋氨氯地平联合盐酸贝那普利对糖尿病肾病合并高血压患者的疗效[J].心血管康复医学杂志,2022,31(4):428-432.
[9] 宋道飞,张爱洁,周慧敏,等. 达格列净通过抑制NLRP3炎性小体缓解糖尿病大鼠肾脏损伤[J].中国中西医结合肾病杂志,2024,25(4):290-294.
[10] 冯舒雅,任常谕,周后凤,等. 达格列净改善2型糖尿病患者肾血管功能、主动脉硬化和血管内皮功能障碍的研究[J].中国医院用药评价与分析,2024,24(4):435-438.
[11] 洪冠宇,纪春敏,刘加河. 达格列净联合胰高血糖素样肽-1受体激动剂对2型糖尿病的疗效研究[J].实用临床医药杂志,2024,28(7):90-95.
[12] 华建军,杨文婷,黄华英,等. 肾脏异位脂肪沉积与早期糖尿病肾脏疾病相关性的研究[J].中国糖尿病杂志,2024,32(5):352-356.
[13] 田黎,崔巍,宋磊,等. 2型糖尿病肾病患者血清cys C、Hcy、尿β2微球蛋白水平及其与肾功能指标的相关性[J].贵州医药,2023,47(1):46-48.